A monthly injection could halt rheumatoid arthritis (RA) in half of all patients, trial data suggests.
The antibody drug tocilizumab works in conjunction with an existing treatment, methotrexate, to stop the condition in which the body attacks its own joints. The drug, which will be sold under the brand name RoActemra by Roche, is awaiting approval
(
Read more... )